One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial

By sjmartinez • June 7, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Jun 5:ciad342. doi: 10.1093/cid/ciad342. Epub ahead of print. PMID: 37279602.

Tags: camostat, covid-19, Infectious Diseases, outpatient, phase 2, Publications, SARS-CoV-2

PrEP as a “Hidden Message”: The Impact of Partner Dynamics on Oral PrEP Adherence Among Cisgender Women in Serodiscordant Relationships

Phuntsog TD, Stockman JK, Amico KR, Kofron R, Morris S, Landovitz RJ, Strathdee S, Moore DJ, Blumenthal J. PrEP as a "Hidden Message": The Impact[...]

Leveraging a large language model to support expansion of surveillance activities to include cardiovascular implantable device infections in a large, integrated national healthcare system

Basnet D, Mull HJ, Morgan DJ, Golenbock SW, Lamkin RP, Strymish JM, Harvey K, Yuen K, Schweizer ML, Drekonja D, Rodriguez-Barradas MC, Branch-Elliman W. Leveraging[...]

Emergence of a novel genotype of extensively drug-resistant Shigella sonnei carrying blaDHA-1 in diverse patient populations, Los Angeles, 2024-2025

Gonzalez-Ferrer S, Shaw B, Fung L, Landovitz RJ, Uslan DZ, Yang S. Emergence of a novel genotype of extensively drug-resistant Shigella sonnei carrying blaDHA-1 in diverse patient populations, Los[...]